271 related articles for article (PubMed ID: 20068111)
1. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
Sportès C; Babb RR; Krumlauf MC; Hakim FT; Steinberg SM; Chow CK; Brown MR; Fleisher TA; Noel P; Maric I; Stetler-Stevenson M; Engel J; Buffet R; Morre M; Amato RJ; Pecora A; Mackall CL; Gress RE
Clin Cancer Res; 2010 Jan; 16(2):727-35. PubMed ID: 20068111
[TBL] [Abstract][Full Text] [Related]
2. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.
Sereti I; Dunham RM; Spritzler J; Aga E; Proschan MA; Medvik K; Battaglia CA; Landay AL; Pahwa S; Fischl MA; Asmuth DM; Tenorio AR; Altman JD; Fox L; Moir S; Malaspina A; Morre M; Buffet R; Silvestri G; Lederman MM;
Blood; 2009 Jun; 113(25):6304-14. PubMed ID: 19380868
[TBL] [Abstract][Full Text] [Related]
3. Perspective on potential clinical applications of recombinant human interleukin-7.
Sportès C; Gress RE; Mackall CL
Ann N Y Acad Sci; 2009 Dec; 1182():28-38. PubMed ID: 20074272
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.
Lévy Y; Sereti I; Tambussi G; Routy JP; Lelièvre JD; Delfraissy JF; Molina JM; Fischl M; Goujard C; Rodriguez B; Rouzioux C; Avettand-Fenoël V; Croughs T; Beq S; Morre M; Poulin JF; Sekaly RP; Thiebaut R; Lederman MM
Clin Infect Dis; 2012 Jul; 55(2):291-300. PubMed ID: 22550117
[TBL] [Abstract][Full Text] [Related]
5. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
Sportès C; Hakim FT; Memon SA; Zhang H; Chua KS; Brown MR; Fleisher TA; Krumlauf MC; Babb RR; Chow CK; Fry TJ; Engels J; Buffet R; Morre M; Amato RJ; Venzon DJ; Korngold R; Pecora A; Gress RE; Mackall CL
J Exp Med; 2008 Jul; 205(7):1701-14. PubMed ID: 18573906
[TBL] [Abstract][Full Text] [Related]
6. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia.
Sheikh V; Porter BO; DerSimonian R; Kovacs SB; Thompson WL; Perez-Diez A; Freeman AF; Roby G; Mican J; Pau A; Rupert A; Adelsberger J; Higgins J; Bourgeois JS; Jensen SM; Morcock DR; Burbelo PD; Osnos L; Maric I; Natarajan V; Croughs T; Yao MD; Estes JD; Sereti I
Blood; 2016 Feb; 127(8):977-88. PubMed ID: 26675348
[TBL] [Abstract][Full Text] [Related]
7. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
8. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM
Clin Cancer Res; 2008 Jun; 14(11):3462-9. PubMed ID: 18519778
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.
Jacobson MA; Hardy D; Connick E; Watson J; DeBruin M
J Infect Dis; 2000 Oct; 182(4):1070-6. PubMed ID: 10979901
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.
Francois B; Jeannet R; Daix T; Walton AH; Shotwell MS; Unsinger J; Monneret G; Rimmelé T; Blood T; Morre M; Gregoire A; Mayo GA; Blood J; Durum SK; Sherwood ER; Hotchkiss RS
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515037
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
12. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
Komschlies KL; Gregorio TA; Gruys ME; Back TC; Faltynek CR; Wiltrout RH
J Immunol; 1994 Jun; 152(12):5776-84. PubMed ID: 8207207
[TBL] [Abstract][Full Text] [Related]
13. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.
Levy Y; Lacabaratz C; Weiss L; Viard JP; Goujard C; Lelièvre JD; Boué F; Molina JM; Rouzioux C; Avettand-Fénoêl V; Croughs T; Beq S; Thiébaut R; Chêne G; Morre M; Delfraissy JF
J Clin Invest; 2009 Apr; 119(4):997-1007. PubMed ID: 19287090
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
15. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.
Fry TJ; Moniuszko M; Creekmore S; Donohue SJ; Douek DC; Giardina S; Hecht TT; Hill BJ; Komschlies K; Tomaszewski J; Franchini G; Mackall CL
Blood; 2003 Mar; 101(6):2294-9. PubMed ID: 12411295
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
17. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC.
Masotti A; Morandini G; Ortolani R; Fumagalli L
Lung Cancer; 1998 Jun; 20(3):191-202. PubMed ID: 9733054
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
Jacobson MA; Spritzler J; Landay A; Chan E; Katzenstein D; Schock B; Fox L; Roe J; Kundu S; Pollard R;
AIDS; 2002 May; 16(8):1147-54. PubMed ID: 12004273
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
[TBL] [Abstract][Full Text] [Related]
20. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
Cebon J; Jäger E; Shackleton MJ; Gibbs P; Davis ID; Hopkins W; Gibbs S; Chen Q; Karbach J; Jackson H; MacGregor DP; Sturrock S; Vaughan H; Maraskovsky E; Neumann A; Hoffman E; Sherman ML; Knuth A
Cancer Immun; 2003 Jul; 3():7. PubMed ID: 12862418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
